Actively Recruiting
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Led by Sun Yat-sen University · Updated on 2025-11-18
55
Participants Needed
1
Research Sites
146 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for those patients is still unknown. This phase 2 clinical trial aims to investigate the objective response rate for unresectable advanced hepatocellular carcinoma.
CONDITIONS
Official Title
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with unresectable advanced-stage hepatocellular carcinoma
- Child-Pugh A or B liver function
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate blood counts: white blood cell count >3×10^9/L, absolute neutrophil count >1.5×10^9/L, platelet count >10×10^9/L, hemoglobin concentration >85 g/L
You will not qualify if you...
- Severe underlying cardiac, pulmonary, or renal diseases
- History of a second primary malignant tumor
- Contraindication to either atezolizumab or bevacizumab
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here